Skip to main content

Table 2 Incidence of AEs classified by SOC and PT

From: Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

System organ class

Preferred term

All grades

N (%)

Grade 3 and 4

N (%)

Blood and lymphatic system disorders

Anemia

178 (89.99)

15 (7.58)

Leukopenia

49 (24.75)

0 (0)

Neutropenia

58 (29.29)

7 (3.54)

Thrombocytopenia

20 (10.10)

0 (0)

Investigations

Alanine aminotransferase increased

20 (10.10)

0 (0)

Aspartate aminotransferase increased

12 (6.06)

1 (0.51)

Creatinine renal clearance decreased

48 (24.24)

0 (0)

Renal and urinary disorders

Renal disorder

1 (0.51)

0 (0)

General disorders and administration site conditions

Drug intolerance

1 (0.51)

0 (0)

No. of Patients with At Least one AE

190 (95.96)

22 (11.11)

  1. AE adverse event